Werewolf Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The 10-Q filing reveals a company in a race against time, attempting to optimize its cost structure and balance sheet before its cash reserves vanish. The successful sale of the 898 program and the elimination of the K2HV loan are positive steps toward cleaning up the capital structure, but they do not solve the fundamental lack of revenue and the high cost of ongoing clinical trials. Investors are now faced with a binary outcome: either the company secures a high-value partnership or acquisition based on the PREDATOR platform's potential, or it collapses under the weight of its own burn rate. The upcoming Q3 2026 data readouts for WTX-124 and WTX-330 represent the final catalysts that will likely determine if the company is a viable acquisition target or a candidate for liquidation.